In Defense of Polypharmacy
1998; Slack Incorporated (United States); Volume: 28; Issue: 4 Linguagem: Inglês
10.3928/0048-5713-19980401-04
ISSN1938-2456
Autores Tópico(s)Schizophrenia research and treatment
ResumoCOMBINATION PHARMACOTHERAPYIn Defense of Polypharmacy Devdutt Navak, MD, , MD Devdutt Navak, MD Published Online:April 01, 1998https://doi.org/10.3928/0048-5713-19980401-04View Full TextPDF 11.2 MB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Nayak DV. Skillful polypharmacy is becoming the practice norm. Paper presented at the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995; Miami. Google Scholar2. Klein DF, Gittelman R. Quitkin F. et. al. Diagnosis And Drug Treatment Of Psychiatric Disorders: Adults And Children; Baltimore, MD: Williams and Wilkins; 1980. Google Scholar3. Kushner SF, Apter JT. Polypharmacy in refractory depression. Psychiatric Times. 1995;12(5):44-46. Google Scholar4. Thase ME, Kupfer DJ. Characteristics of treatment-resistant depression: In: Zohar J. Belmaker RM, eds. Treating Resistant Depression. New York: PMA Publishing; 1987:23-45. Google Scholar5. National Center for Health Statistics, NAMCS, Micro-data tape documentation. Hyattsville, MD: National Center for Health Statistics; 1989. Google Scholar6. Nichol MD, Stimmel GF, Lange SC. Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry. 1995;56(2):60-66. Google Scholar7. Poet RM. Treatment of refractory affective disorders: Presented at psychopharmacology in practice clinical and research update. 1996;56(2) 60-66. Google Scholar8. Messenheimer JA. Treatment of seizures. In Dornbrand L, Hoole AJ, Picard CG eds. Manual Of Clinical Problems In Adult Ambulatory Care. 2nd edition. Little, Brown & Co; 1992. Google Scholar9. Rogers CS. Evaluation and treatment of hypertension. In: Dombrand L, Hoole, AJ, Richard CG eds. Manual Of Clincial Problems In Adult Ambulatory Care, 2nd Edition; Little, Brown & Co; 1992. Google Scholar10. Goodman WK. Recent developments in neurobiology of obsessive compulsive disorder. J Clin Psychiatry. 1996;57(10):500. Google Scholar11. Kane J. Marder J. Psycbopharmacology of schizophrenia. Schuophr Bull. 1993;19:287-302. Google Scholar12. O'Connell RA, Mayo JA1 Flatlow L, et.al. Outcome of bipolar on long term treatment with lithium. Br J Psychiatry. 1991 ;( 159)123-129. Google Scholar13. Marrow M, Goldberg JF, Rossman LS, et al. Outcome in manic disorders. Arch Gen Psychiatry. 1990;47:665-671. Google Scholar14. Grunhans L, Rabin D, G reden JF. Simultaneous panic and depressive disorder: response to antidepressant treatment. J Clin Psychiatry. 1986;47:4-7. Google Scholar15. Amsterdam JD. Refractory depression. In: Advances In Neuropsychiatry And Psychopharmacology Vol. 2; New York: Raven Press, Ltd.; 1993. Google Scholar16. Lin EHB, Vonkorff M. Katon W, et. al. The role of the primary care physician in patients ' adherence to antidepressant therapy. Med Care. 1995;33:67-74. Google Scholar17. Callan AM, Fava M, Rosenbaum JF. Drug interactions in Phychopharmacology. In: Psychiatr Clin North Amer. 1993;2( 16):3. Google Scholar18. Nemeroff CB, Devance CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:3. Google Scholar19. Riesenman C. Antidepressant and drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy. 1995:15:6 pt. 2:845-995. Google Scholar20. Ereshefaky L. Pharmacokinetics and drug interactions; update for new antipsychotics. J Clin Psychiatry. 1996;57(Suppl.II). Google Scholar21. Eichelbaum M, Grose AS. The genetic polymorphism of debrisoquine/sparteire metabolism: clinical aspects. Pkarmacolo Ther. 1990;46:377-394. Google Scholar22. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry. 1994;2:204-213. Google Scholar23. Vandel S. Bertschy G., Bonin B. et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Pharmacopsychiatry. 1 992;25:202-207. Google Scholar24. McElroy SL, Keck PE Jr, Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry. 1995;56(2suppl.);49-55. Google Scholar25. Remick RA. Anticholinergic side effects of tricyclic antidepressants and their management. Neuropsyckopharmacology and Biological Psychiatry. 1988;12:225-231. Google Scholar26. Goldenberg AJ. Pylocarpine for anticholinergic side effects. Biol Ther Psychiatry Newlett. 1995;18:6. Google Scholar27. Goldenberg AJ. Dopamine agonists; antidepressant adjuncts. Biol Ther Psychiatry Newlett. 1994:17-20. Google Scholar28. McElroy SL, Keck PE, Friedman LM. Practical management of antidepressant side effects. In: Yudolsky SC, ed. An Update Of Practical Clinical Strategies In Treating Depression And Anxiety Disorders In A Managed Care Environment. Washington, DC: American Psychiatric Association; 1996. Google Scholar29. Gitlin MJ. Psychotropic medication and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry. 1994;6:13-15. Google Scholar30. Steward JW, Harrison W, Quitkin F, et al. Phenelzine induced pyridozine deficiency. J Clin Psychopharmacol. 1984;4:225-226. Google Scholar31. Pollack MH, Rosenbaum JF. Management of antidepressant induced side effects: a practical guide for the clinician. J Clin Psychiatry. 1987;48:3-8. Google Scholar32. Lin EHB, VonKorff M, Katon W, et al. The role of the primary care physician in-patients adherence to antidepressant therapy. Med Care. 1995;33:67-74. Google Scholar33. Zajecka JM. Managing anxiety when complicated by other conditions. Presentation at the Annual U.S, Psychiatric Mental Health Congress. Washington, DC: November 17, 1994. Google Scholar34. Zajecka JM, Ross JS. Treatment of depression complicated by anxiety. In: Hales RE, Yudofaky SC, eds. Practical Clinical Strategies In Treating Depression And Anxiety Disorders In A Managed Care Environment; Washington, DC: American Psychiatric Association; 1996. Google Scholar35. Judd LL. Rappaport MM, Paulus MP, et al. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry. 1994;55:4<8uppl):18-28. Google Scholar36. Hogarty GE. McEvoy JP. Ulrich RF. et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry. 1995;52:29. Google Scholar37. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry. 1992;31:698-704. Google Scholar38. Goodwin FK. An integrative approach to affective disorders. In: Psychopharmacology In Practice: Clinical And Research Update. Bethesda. MD: Federation for the advancement of education in sciences; 1993. Google Scholar39. Post RMS, Leverich GS, Altschuler LL, et al. Lithium discontinuation induced refractoriness: preliminary observations. Am J Psychiatry. 1992;149:1727-1729. Google Scholar40. Goodwin FK, Jamison KR. Manic Depressive Illness. New York: Oxford University Press; 1990. Google Scholar41. Post RMS, Weirs SRB. The neurobiology of treatment-resistant mood disorders in psychopharmacology. In: Blood FE, Kupfer DJ. The Fourth Generation Of Progress. New York: Raven Press, Ltd.; 1995. Google Scholar42. Regier DA, Burke JD Jr, Burke KC. Comorbidity of affective anxiety disorders in the NIMH epidemiologic catchment area program. In: Maser JD, Cloninger CR. Comorbidity Of Mood And Anxiety Disorders (Suppl). Washington. DC: American Psychiatric Press; 1990. Google Scholar43. Wittchen HU, Zhao S, Kessler RC, et al DSM IHR Generalized anxiety disorder with the national comorbidity survey. Arch Gen Psychiatry. 1994;51:355-364. Google Scholar44. Kushner MG, Sher KJ, Butman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry. 1990;147:685-695. Google Scholar45. Drake RE, Osher FC, Nourdsy DL, et al. Diagnosis of alcohol issue disorders in schizophrenia. Schizophr Bull. 1990;16:57-67. Google Scholar46. Clayton PJ. The comorbidity factor: establishing the primary diagnosis in patients with mized symptoms of anxiety and depression. J Clin Psychiatry. 1990;51(suppl):35-39. Google Scholar47. Mueser KT. Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates, Schuophr Bull. 1990;16:31-56. Google Scholar48. Hyman SE. Nestler EJ. The Molecular Foundations Of Psychiatry. Washington DC: American Psychiatric Press; 1993. Google Scholar49. Hyman SE, Coyle JT. The neuroscientific foundations of psychiatry. In: Hales RE, Yudofsy SC.Talbott JA Textbook Of Psychiatry. Washington, DC: American Psychiatry Press; 1994. Google Scholar50. Dubovsky SL, Murphy J, Christiano J, et al. The calcium second messenger system in bipolar disorders: data supporting new research directions. Neuropsychiatry Clinical Neuroscience. 1992;4:3-14. Google Scholar51. VanPraag HM. Two tier diagnosing in psychiatry. Psychiatry lies. 1990;34:1-11. Google Scholar52. Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new seotonergic agents. J Clin Psychiatry. l994;55:2(suppl):34-44. Google Scholar53. Duboveky SLApproacbes to developing new anxiolytics and antidepressants. J Clin Psychiatry. 1993;54:5(supplk75-83. Google Scholar54. Heninger GR. The role of serotonin in clinical disorders in psychopharmacology. In Bloom FE, Kupfer DJ, eds. The Fourth Generation Of Progress. New York: Raven Press, Ltd. 1995. Google Scholar55. Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry. I995;56(suppl2 ):38-48. Google Scholar Previous article Next article FiguresReferencesRelatedDetails Request Permissions InformationCopyright 2013, SLACK Incorporated
Referência(s)